Literature DB >> 8220297

Vitamin E in extrapyramidal disorders.

L Bischot1, G Van den Brink, A J Porsius.   

Abstract

In this article the effect of vitamin E on two extrapyramidal disorders, tardive dyskinesia and Parkinson's disease, is reviewed. After a brief description of the symptoms, the current hypotheses for the pathogenesis of these diseases are described. A summary of the clinical research that has been done to establish the effectiveness of vitamin E is given. In tardive dyskinesia four clinical trials (double-blind, placebo-controlled) showed improvement in the symptoms with vitamin E in doses of up to 1,600 IU/day. Preliminary studies concerning Parkinson's disease suggested that vitamin E (2,000 IU/day) probably cannot prevent the development of the disease. It was suggested that vitamin E is able to slow the progression of the illness. The results from a large double-blind, placebo-controlled clinical trial, however, did not show any beneficial effect of vitamin E in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8220297     DOI: 10.1007/bf01880556

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  27 in total

Review 1.  [Selegiline in Parkinson's disease; symptomatic or causal effect?].

Authors:  E C Wolters; M A Kuiper; M W Horstink
Journal:  Ned Tijdschr Geneeskd       Date:  1992-08-08

Review 2.  Do environmental toxins cause Parkinson's disease? A critical review.

Authors:  C M Tanner; J W Langston
Journal:  Neurology       Date:  1990-10       Impact factor: 9.910

3.  Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia.

Authors:  J B Lohr; R Kuczenski; H S Bracha; M Moir; D V Jeste
Journal:  Biol Psychiatry       Date:  1990-09-15       Impact factor: 13.382

Review 4.  Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E.

Authors:  J L Cadet; J B Lohr
Journal:  Ann N Y Acad Sci       Date:  1989       Impact factor: 5.691

Review 5.  Vitamin E and cardiovascular disease.

Authors:  J Kleijnen; P Knipschild; G ter Riet
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 6.  MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture.

Authors:  S H Snyder; R J D'Amato
Journal:  Neurology       Date:  1986-02       Impact factor: 9.910

Review 7.  Vitamin E and the neonate.

Authors:  R A Ehrenkranz
Journal:  Am J Dis Child       Date:  1980-12

Review 8.  Antioxidant therapy in Parkinson's disease.

Authors:  J D Grimes; M N Hassan; J Thakar
Journal:  Can J Neurol Sci       Date:  1987-08       Impact factor: 2.104

9.  DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group.

Authors: 
Journal:  Arch Neurol       Date:  1989-10

10.  Tardive dyskinesia: managing a common neuroleptic side effect.

Authors:  D V Jeste; A J Krull; K Kilbourn
Journal:  Geriatrics       Date:  1990-12
View more
  3 in total

1.  No association between a functional NAD(P)H: quinone oxidoreductase gene polymorphism (Pro187Ser) and tardive dyskinesia.

Authors:  Hiroko Hori; Takahiro Shinkai; Chima Matsumoto; Osamu Ohmori; Jun Nakamura
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

2.  Genetic association analysis of neuronal nitric oxide synthase gene polymorphism with tardive dyskinesia.

Authors:  Takahiro Shinkai; Osamu Ohmori; Chima Matsumoto; Hiroko Hori; James L Kennedy; Jun Nakamura
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

3.  Natural plant products and extracts that reduce immunoexcitotoxicity-associated neurodegeneration and promote repair within the central nervous system.

Authors:  Russell L Blaylock; Joseph Maroon
Journal:  Surg Neurol Int       Date:  2012-02-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.